Progression-free survival (PFS) and overall survival (OS) in phase HI trials of systemic chemotherapy in advanced non-small cell lung cancer (NSCLC).

被引：0
|
作者：
Hotta, K.
Kiura, K.
Takigawa, N.
Tabata, M.
Fujiwara, Y.
Tanimoto, M.
机构：
[1] Okayama Univ, Grad Sch Med, Dept Hematol Oncol & Resp Med, Okayama, Japan
[2] Okayama Univ Hosp, Dept Resp Med, Okayama, Japan
[3] Okayama Univ Hosp, Ctr Clin Oncol, Okayama, Japan
[4] Okayama Univ, Tsuyama Cent Hosp, Okayama, Japan
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2010年 / 28卷 / 15期
关键词：
D O I：
10.1200/jco.2010.28.15_suppl.7624
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
7624
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Influence of crossover therapy on the association between progression-free survival (PFS) and overall survival (OS) in randomized trials of molecular-targeted agents for advanced non-small cell lung cancer (NSCLC).
    Hotta, K.
    Kiura, K.
    Suzuki, E.
    Takigawa, N.
    Fujiwara, Y.
    Ichihara, E.
    Tabata, M.
    Tanimoto, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [2] Insulin-like growth factor binding proteins related to progression-free survival (PFS) and overall survival (OS) in advanced non-small cell lung cancer (NSCLC) patients treated with chemotherapy
    Karmali, R.
    Fidler, M. J.
    Cela, I.
    Olmsted, G.
    Rouhi, O.
    Basu, S.
    Walters, K. K.
    Coon, J.
    Bonomi, P.
    Borgia, J. A.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [3] Time trends in overall survival (OS) and progression-free survival (PFS) in the first-line treatment of advanced non-small-cell lung cancer (NSCLC).
    Rutkowski, Jacek
    Saad, Everardo D.
    Buyse, Marc E.
    Jassem, Jacek
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [4] OVERVIEW OF PRIMARY ENDPOINTS, PROGRESSION-FREE SURVIVAL (PFS) AND OVERALL SURVIVAL (OS) FOR NON-SMALL CELL LUNG CANCER (NSCLC): THEIR VALUE IN TREATMENT DECISIONS AND PATIENT CARE
    Heron, Louise
    Chouaid, Christos
    Vergnenegre, Alain
    Bischoff, Helge
    Walzer, Stefan
    JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (06) : S1447 - S1448
  • [5] OVERVIEW OF PRIMARY ENDPOINTS, PROGRESSION-FREE SURVIVAL (PFS) AND OVERALL SURVIVAL (OS) FOR NON-SMALL CELL LUNG CANCER (NSCLC): THEIR VALUE IN TREATMENT DECISIONS AND PATIENT CARE
    Heron, L.
    De Castro Carpeno, J.
    Chouaid, C.
    Vergnenegre, A.
    Bischoff, H. G.
    Walzer, S.
    VALUE IN HEALTH, 2011, 14 (03) : A177 - A178
  • [6] Progression-Free Survival (PFS) as a Surrogate for Overall Survival (OS) in Advanced Non-Small Cell Lung Cancer (aNSCLC): Analysis of Patient-Level Pooled Randomized Clinical Trials (RCTs)
    Ports, Kayleen
    Chen, Weixi
    Aptekar, Jacob
    Jain, Rahul
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2024, 33 : 178 - 178
  • [7] Progression-free survival (PFS) as a surrogate for overall survival (OS)
    Stewart, David J.
    Bosse, Dominick
    Hilton, John
    Goss, Glenwood
    Fung-Kee-Fung, Michael
    Jonker, Derek
    CANCER RESEARCH, 2018, 78 (13)
  • [8] Rethinking Progression-Free Survival (PFS) as a Clinical Trials Surrogate for Overall Survival (OS)
    Stewart, D.
    Bosse, D.
    Ocana, A.
    Goss, G.
    Jonker, D.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S1782 - S1782
  • [9] VALUE OF PROGRESSION-FREE SURVIVAL (PFS) IN REFRACTORY NON-SMALL CELL LUNG CANCER (NSCLC): AN EXPLORATORY MODELING ANALYSIS
    Ferrufino, C. P.
    Foley, D.
    Trochlil, K.
    Munakata, J.
    VALUE IN HEALTH, 2011, 14 (07) : A447 - A447
  • [10] Use of progression-free survival (PES) as an endpoint in advanced non-small cell lung cancer (NSCLC) trials: FDA perspective
    Malik, S. M.
    Ibrahim, A.
    Sridhara, R.
    Justice, R. L.
    Pazdur, R.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
12345